Acumen Pharmaceuticals Investor Relations Material

Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company primarily engaged in the discovery and development of therapies for the treatment of Alzheimer's disease. The company's most advanced candidate is ACU193, a humanized monoclonal antibody designed to target toxic soluble amyloid-beta oligomers. These amyloid-beta oligomers are associated with the neurodegeneration seen in Alzheimer’s disease patients. Acumen Pharmaceuticals was founded in 1996 and focuses on progressing its immunotherapy approach to offer potential disease-modifying treatments. The company is headquartered in Charlottesville, Virginia, and its shares are listed on the NASDAQ.